Shattuck Labs, Inc. (STTK)
| Market Cap | 392.47M |
| Revenue (ttm) | 1.28M |
| Net Income (ttm) | -64.83M |
| Shares Out | 42.25M |
| EPS (ttm) | -1.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,150,214 |
| Open | 10.71 |
| Previous Close | 10.01 |
| Day's Range | 9.23 - 9.99 |
| 52-Week Range | 9.81 - 60.52 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 46.50 (+400.5%) |
| Earnings Date | Nov 12, 2021 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in A...
Financial Performance
In 2020, Shattuck Labs's revenue was $9.93 million, an increase of 0.48% compared to the previous year's $9.89 million. Losses were -$36.60 million, 52.6% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Shattuck Labs stock is "Strong Buy." The 12-month stock price forecast is 46.50, which is an increase of 400.54% from the latest price.
News
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Enco...
LOS ANGELES--(BUSINESS WIRE)---- $STTK #STTK--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK
NEW YORK, Nov. 25, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK). Such investors are advised to co...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encoura...
LOS ANGELES--(BUSINESS WIRE)---- $STTK #STTK--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc.
EQUITY ALERT: Rosen Law Firm Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Inves...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Shattuck Labs, Inc. (NASDAQ: STT...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK). Such investors are advised to c...
Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-1721...
– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients –
Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights
– Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials rem...
Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy o...
– Event scheduled for Friday, November 12, 2021 at 8:00 a.m. ET –
Shattuck Labs Announces Participation in Upcoming November Investor Conferences
AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...
Shattuck Labs Announces Changes to its Board of Directors
Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D.; Dr. George Golumbeski, Ph.D., appointed as Chairman of the Board Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D...
Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society...
AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...
Shattuck Labs Announces Participation in Upcoming September Conferences
AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...
Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 a...
– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunoth...
Shattuck Labs Announces Participation in the BTIG Biotechnology Conference
AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...
Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021
AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...
Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer
AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...
Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –
Shattuck Labs Announces Participation in Upcoming May Conferences
AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...
Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusio...
Shattuck Labs Announces Participation in Needham's 20th Annual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...
Shattuck Labs Announces Promotion of Andrew R. Neill to Chief Financial Officer
AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...
Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –
Shattuck Labs to Present Two Posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...
Shattuck Labs Announces Participation in Citi's 2021 Virtual Immuno-Oncology Day
AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion protei...